.Charles Baum, M.D., Ph.D., who supervised Mirati Therapeutics' $ 5.8 billion sale to Bristol Myers Squibb in 2014, is actually taking the helm of youthful biotech Terremoto Biosciences.Baum's "extensive expertise in medicine growth, and tried and tested track record earlier high-impact medicines, will certainly be instrumental," outbound chief executive officer Peter Thompson, M.D., claimed in a July 25 release. Thompson will preserve his chair as board chairperson..Baum, an experienced physician-scientist, was actually the owner, head of state as well as CEO of oncology-focused Mirati. Just before that, he helped create cancer drugs at Pfizer and also Schering-Plough..
Charles Baum, M.D., Ph.D.(( Mirati)).Now, Baum will function as CEO at Terremoto, a business establishing small molecules to target disease-causing healthy proteins-- like those found in malignant growth cells-- making use of covalent connections. Existing treatments that use covalent connects largely target the amino acid cysteine. However, of the twenty amino acids that comprise proteins, cysteine is the least typical. Terremoto is actually instead targeting some of the essential amino acids, amino acid lysine, which is located in almost all healthy proteins.By targeting amino acid lysine and also various other amino acids, Terremoto wants to address previously undruggable diseases and create first-in-class medicines..The biotech, based in South San Francisco, increased $75 million in set A financing in 2022. A little more than a year eventually, the biotech much more than doubled that amount in a $175 thousand set B.